|Ms. Jill C. Milne||Co-Founder, CEO, Pres & Director||716.96k||N/A||1968|
|Dr. Andrew J. Nichols||Chief Scientific Officer||544.24k||N/A||1961|
|Mr. Noah Clauser CPA||Chief Financial Officer||N/A||N/A||1973|
|Mr. Benjamin S. Harshbarger J.D.||Sr. VP & Gen. Counsel||N/A||N/A||1969|
|Ms. Keri McGrail||Sr. VP of HR||N/A||N/A||N/A|
|Ms. Andrea L. Matthews||Sr. VP of Corp. Affairs||N/A||N/A||N/A|
|Mr. Andrew A. Komjathy||Chief Commercial Officer||N/A||N/A||1964|
Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.
Catabasis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 10; Compensation: 10.